English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduSt. Jude Children’s Research Hospital study highlights the power of comprehensive whole genome, whole exome and RNA sequencing to better understand and treat each patient’s cancer.
Tag: Pediatric Cancer
Scientists link frailty and neurocognitive decline in childhood cancer survivors
St. Jude Children’s Research Hospital scientists have shown that frailty contributes to neurocognitive decline in young adult survivors of childhood cancer.
Melanoma registry results shine light on rare pediatric cancer
St. Jude Children’s Research Hospital scientists created a registry for molecular analysis of pediatric melanoma that provides insight into treatment.
#TeamTKC Captain Eli Manning Helps Launch Inaugural Virtual 5K to Tackle Kids Cancer
#TeamTKC Captain Eli Manning Helps Launch Inaugural Virtual 5K to Tackle Kids Cancer
Low-calorie diet and mild exercise improve survival for young people with leukemia
A study led by researchers at UCLA and CHLA has shown that a combination of modest dietary changes and exercise can dramatically improve survival outcomes for those with acute lymphoblastic leukemia, the most common childhood cancer.
Cecelia Calhoun Named Director of the Adolescent-Young Adult Sickle Cell Program at Yale Cancer Center and Smilow Cancer Hospital
Cecelia Calhoun, MD, MSPH, MBA, has been appointed Assistant Professor of Medicine (Hematology) and Assistant Professor of Pediatrics (Hematology/Oncology) at Yale Cancer Center and Smilow Cancer Hospital
ATRT molecular groups: looking at the biology from the clinic
Scientists at St. Jude Children’s Research Hospital are learning more about what the molecular groups of a rare pediatric brain tumor mean for clinical care.
Alex’s Lemonade Stand Foundation Awards More than $18.5 Million to Recipients of Crazy 8 Initiative to Advance Pediatric Cancer Research
In the spirit of growing scientific collaboration, grants will provide support for four projects across 15 research institutions using cutting-edge technology to address crucial issues in pediatric cancer research
Socioeconomic status plays a major role in cognitive outcomes
Childhood cancer and its treatment can result in cognitive struggles. St. Jude scientists are studying the risk factors.
New NCCN Guidelines Analyze Evidence for Cancer Type Found Almost Exclusively in Children
National Comprehensive Cancer Network publishes first-ever complete medical guidelines for a pediatric solid tumor, so children everywhere receive the best care based on the latest research. NCCN Guidelines for Wilms Tumor shares information for earlier, safer diagnosis and treatment in effort to reduce disparities; doctors warn of late diagnosis as a possible impact from the COVID-19 pandemic.
Study reveals mutations that drive therapy-related myeloid neoplasms in children
Research from scientists at St. Jude Children’s Research Hospital found mutations up to two years before cancer developed, showing an opportunity for early interventions.
From the clinic to the lab, understanding medulloblastoma relies on molecular profiling
A pair of research papers from St. Jude Children’s Research Hospital report on a medulloblastoma clinical trial that provides insights to guide treatment and shed light on relapsed disease.
CHOP Researchers Find NTRK Fusions More Common than Expected in Pediatric Tumors
In a large study of pediatric cancer patients, researchers from Children’s Hospital of Philadelphia (CHOP) have analyzed the frequency, fusion partners, and clinical outcome of neurotrophic tyrosine receptor kinase (NTRK) fusions, which are clinical biomarkers that identify patients suitable for treatment with FDA-approved TRK inhibitors. The researchers found that NTRK fusions are more common in pediatric tumors and also involve a wider range of tumors than adult cancers, information that could help prioritize screening for NTRK fusions in pediatric cancer patients who might benefit from treatment with TRK inhibitors.
Hackensack Meridian Health’s Tackle Kids Cancer Celebrates Five Years of Support to Fight Pediatric Cancer and Raises more than $10 Million
Philanthropic initiative of the Children’s Cancer Institute, reaches five year milestone combatting pediatric cancer
Studying Patterns of Relapse in Pediatric Hodgkin Lymphoma using a Response-Based Therapy Approach
Recent research from Rutgers Cancer Institute of New Jersey expert as part of a phase 3 study from the Children’s Oncology Group explores response-based consolidation with modern radiation therapy as safe and effective standard of care for pediatric Hodgkin lymphoma patients. This work is being presented at the Annual Meeting of the American Society for Radiation Oncology (ASTRO) this week.
Tumor DNA in Spinal Fluid Could Help Doctors Better Monitor Childhood Brain Cancer
Researchers have demonstrated that a new liquid biopsy approach overcomes traditional barriers to quickly and efficiently diagnose and monitor high-grade pediatric gliomas.
New Guidelines for Maximizing Cures and Minimizing Side Effects in Children with Hodgkin Lymphoma
The National Comprehensive Cancer Network announces publication of new NCCN Guidelines for Pediatric Hodgkin Lymphoma, one of the most curable forms of pediatric cancer. They synthesize the latest evidence and expert-consensus to make sure every child receives appropriate, but not excessive, treatment.
UChicago bioinformatics team to create data infrastructure for global pediatric cancer initiative
The University of Chicago Pediatric Cancer Data Commons and The Leukemia and Lymphoma Society are working together to bring precision medicine to children and young adults with acute leukemia.
$500,000 gift supports worldwide effort to harness pediatric cancer data to advance treatment for children
Family looks to the ‘bright side’ by creating a charity to support pediatric cancer research and providing UChicago Medicine Comer Children’s Hospital with $500,000 gift.
New Treatment Developed by Children’s Hospital of Philadelphia Shows Success in High-Risk Solid Tumors
In a breakthrough study, researchers at Children’s Hospital of Philadelphia (CHOP) have shown that an enhanced treatment developed in their lab leads to long-term remissions in 80% to 100% of mice with drug-resistant or high-risk solid tumors. The research, which could soon lead to clinical trials, is described in Cancer Research, a journal of the American Association for Cancer Research.
Brain Cancer: UVA IDs Gene Responsible for Deadly Glioblastoma
The discovery of the oncogene responsible for glioblastoma could be the brain tumor’s Achilles’ heel, one researcher says.
Tackle Kids Cancer Receives $250,000 Gift from Sohn Conference Foundation to Benefit Pediatric Cancer and Patient Care at Hackensack Meridian Health
Foundation receives generous donation from corporate partner to combat pediatric cancer and benefit patient care
St. Jude Cloud portal expands access to treasure trove of pediatric solid tumor data
St. Jude Children’s Research Hospital develops the Childhood Solid Tumor Network data portal to speed discoveries and novel therapies for treatment of childhood solid tumors
St. Jude Children’s Research Hospital president, CEO recognized for contributions to cancer research
The American Association for Cancer Research honored St. Jude President and CEO James R. Downing, M.D., with its inaugural AACR-St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research.
Children’s Hospital Los Angeles Ranked No. 1 Children’s Hospital in the Western U.S., No. 5 Nationally for Second Straight Year
Children’s Hospital Los Angeles (CHLA) ranks again among the nation’s premier destinations for pediatric care, according to the U.S. News & World Report Best Children’s Hospitals annual list released today. Hospital retains national No. 5 ranking and is highest scoring children’s hospital in Western United States.
MSK Kids Study: Children with Cancer are Not at a Higher Risk for COVID-19 Infection or Morbidity
Researches from MSK Kids at Memorial Sloan Kettering Cancer Center (MSK) found that children with cancer are not at a higher risk of being affected by COVID-19.
Angiotensin Hormone’s Protective Effects Could Improve Cancer Treatment
Article title: Angiotensin-(1–7) reduces doxorubicin-induced cardiac dysfunction in male and female Sprague-Dawley rats through antioxidant mechanisms Authors: Omeed Rahimi, Jay Kirby, Jasmina Varagic, Brian Westwood, E. Ann Tallant, Patricia E. Gallagher From the authors: “[Angiotensin]-(1–7) is a clinically safe peptide hormone with cardioprotective…
Inherited mutation can predispose children to a type of brain tumor
Collaboration co-led by researchers at St. Jude Children’s Research Hospital discovers a novel predisposition gene in pediatric medulloblastoma.
Targeting a transporter to treat SHH medulloblastoma
Scientists at St. Jude Children’s Research Hospital have identified a novel target for a type of pediatric brain tumor.
Post-diagnosis disparities drive poorer outcomes for pediatric Black and Hispanic brain cancer patients
Of 1,881 patients under age 19 diagnosed with cancers of the brain and central nervous system between 2000 and 2015, 52 percent of White patients lived five years from diagnosis, whereas only 44 percent of African American patients and 45 percent of Hispanic patients reached a similar milestone.
Pediatric Oncologist Ching-Hon Pui, M.D., receives Medal of Honor from the American Cancer Society
St. Jude Children’s Research Hospital pediatrician and researcher is honored for significant contributions to the advancement and impact of global collective efforts to save more lives from childhood cancer.
Combination Drug Therapy For Childhood Brain Tumors Shows Promise In Laboratory Models
In experiments with human cells and mice, researchers at the Johns Hopkins Kimmel Cancer Center report evidence that combining the experimental cancer medication TAK228 (also called sapanisertib) with an existing anti-cancer drug called trametinib may be more effective than either drug alone in decreasing the growth of pediatric low-grade gliomas. These cancers are the most common childhood brain cancer, accounting for up to one-third of all cases. Low grade pediatric gliomas arise in brain cells (glia) that support and nourish neurons, and current standard chemotherapies with decades-old drugs, while generally effective in lengthening life, often carry side effects or are not tolerated. Approximately 50% of children treated with traditional therapy have their tumors regrow, underscoring the need for better, targeted treatments.
New website powered by St. Jude informs families facing childhood cancer no matter where the patient receives treatment
The Together website by St. Jude offers information about diseases, diagnosis and treatment options, as well as supportive care resources and shared stories of hope, healing and experience.
February is Cancer Prevention Month
Along with a healthy lifestyle, regular screening can help with the prevention of cancer. Rutgers Cancer Institute of New Jersey experts share additional information during this Cancer Prevention Month.
The Pediatric Cancer Genome Project at 10: The impact lives on
Ten years ago this week St. Jude Children’s Research Hospital and Washington University School of Medicine unveiled an ambitious collaboration to identify the genetic changes that lead to some of the world’s deadliest childhood cancers. The researchers proposed a three-year, $65 million project to sequence the complete normal and cancer genomes of more than 600 childhood cancer patients.
Partnership with China prompts change in care for high-risk type of leukemia
Researchers from St. Jude Children’s Research Hospital and the Chinese Children’s Cancer Group led the first randomized, Phase III clinical trial comparing targeted therapies for acute lymphoblastic leukemia (ALL) driven by the Philadelphia chromosome. Results showed that the drug dasatinib provides more benefit than the standard of care, which led to changes in the way this leukemia is treated. The findings were reported today in JAMA Oncology.
$150K Pledge from Om Foundation to Support Pediatric Cancer Research at Rutgers Cancer Institute of New Jersey
A $150,000 pledge from the Om Foundation will aid investigators at Rutgers Cancer Institute of New Jersey in examining a certain type of medication that impacts gene activity in the treatment of a form of pediatric brain cancer.
Treating the TOTAL patient: clinical trial reduces relapse
A St. Jude Children’s Research Hospital study lowered the rate of relapse for patients with acute lymphoblastic leukemia.
Major Grant for Study of Cell Fate in Cancer
HMS scientist’s work will aim to elucidate the role of cellular decision-making in cancer development
St. Jude Children’s Research Hospital and IAEA partner to tackle childhood cancers in developing countries
The International Atomic Energy Agency (IAEA) and St. Jude Children’s Research Hospital are joining forces to combat childhood cancers in developing countries.
Research on firearm injuries to U.S. children gets 30 times less funding per death than other causes
Firearm injuries kill 2,500 American children each year. But the nation spends far less on studying what led to these injuries, and what might prevent and treat them, than it spends on other causes of death in children. In fact, on a per-death basis, funding for pediatric firearm research is 30 times lower than it would have to be to keep pace with research on other child health threats.
Algorithm Reduces Need for Therapy in Children With Intermediate-Risk Neuroblastoma
Roswell Park’s Dr. Clare Twist led an effort to develop and validate a new treatment algorithm for infants and children with neuroblastoma. In a new study in the Journal of Clinical Oncology, the team reports that many patients can safely receive less extensive therapy.
Leukemia Drug Shows Promise for Treating a Childhood Brain Cancer
Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego researchers describe new use of leukemia drug, nilotinib, to treat subtype of medulloblastoma, a deadly pediatric brain cancer.
Pain Clinic Provides Safe Space for Sickle Cell Patients to Receive Treatment
With the aim of improving pain control and decreasing hospitalizations for vaso-occlusive crisis, the Sickle Cell Team at Children’s of Alabama is moving to implement individualized pain plans for patients and pilot an outpatient pain clinic.
Cancer Predisposition Clinic Aims To Change Trajectory Of Genetically Based Cancer
Children’s of Alabama’s Cancer Predisposition Clinic physicians develop personalized screening for children who have inherited cancer predisposition syndromes with hopes that early detection will lead to improved outcomes.
Birmingham Woman Meets Philadelphia Man Who Saved Her Life Through Bone Marrow Donation
Jada Lucas, a 22-year-old bone marrow recipient from Birmingham, met the bone marrow donor who helped save her life — Jerome Lewis of Philadelphia, Penn. — at donor registry event at Children’s of Alabama.